Safety and Efficacy of Atezolizumab, Obinutuzumab and Venetoclax Combination for Relapsed/Refractory Non-Hodgkin Lymphomas: Results From the Safety-Run of a Lysa Study

Hematological Oncology - United Kingdom
doi 10.1002/hon.144_2630
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Wiley

Related search

PHASE 1B STUDY OF ViPOR (VENETOCLAX, IBRUTINIB, PREDNISONE, OBINUTUZUMAB, LENALIDOMIDE) IN RELAPSED/REFRACTORY B-Cell LYMPHOMA: SAFETY, EFFICACY AND MOLECULAR ANALYSIS

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Results From the Safety Run-In Period of the Sympatico Study Evaluating Ibrutinib in Combination With Venetoclax in Patients With Relapsed/Refractory Mantle Cell Lymphoma

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Efficacy and Safety of Obinutuzumab + Lenalidomide + Atezolizumab in Patients With Relapsed or Refractory Follicular Lymphoma: Primary Analysis of a Phase 1b/2 Trial

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Phase Ib Study of Cc-122 in Combination With Obinutuzumab (Ga101): Relapsed or Refractory (R/R) Patients With B-Cell Non-Hodgkin Lymphomas (Nhl)

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2017English

Venetoclax (Ven) in Patients With Relapsed/Refractory Non-Hodgkin Lymphoma (Nhl)

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2017English

Bianca: A Phase 2 Study of the Safety and Efficacy of Tisagenlecleucel in Pediatric Patients With Relapsed/Refractory Mature B-Cell Non-Hodgkin Lymphoma

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Efficacy of Chemotherapy or Chemo-Anti-Pd-1 Combination After Failed Anti-Pd-1 Therapy for Relapsed and Refractory Hodgkin Lymphoma: A Series From Lysa Centers

American Journal of Hematology
Hematology
2018English

Phase 1b Study of Venetoclax-Obinutuzumab in Previously Untreated and Relapsed/Refractory Chronic Lymphocytic Leukemia

Blood
BiochemistryImmunologyCell BiologyHematology
2019English

Comparison of Efficacy of Pembrolizumab Between Epstein-Barr Virus‒Positive and ‒Negative Relapsed or Refractory Non-Hodgkin Lymphomas

Cancer Research and Treatment
Cancer ResearchOncology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy